title: The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women.
abstract: OBJECTIVE
  To investigate the changes in plasma lipids and lipoproteins, low-density lipoprotein (LDL) oxidizability, and plasma homocysteine during postmenopausal sequential 3-monthly hormone replacement therapy.
  
  
  METHODS
  Open longitudinal prospective study.
  
  
  METHODS
  Gynecological outpatient department of a university hospital.
  
  
  METHODS
  Thirty-nine healthy nonhysterectomized postmenopausal women.
  
  
  METHODS
  Oral conjugated estrogen, 0.625 mg/d, combined with oral medrogestone 10 mg/d during the last 14 days of each 84-day treatment cycle. The treatment was given for four treatment cycles of 84 days (1 year).
  
  
  METHODS
  Plasma lipids and lipoproteins, LDL oxidizability, and plasma homocysteine.
  
  
  RESULTS
  After 1 year of treatment plasma concentrations of total cholesterol and LDL cholesterol were 3.5% and 8.7% lower, respectively. High density lipoprotein cholesterol, apolipoprotein A-I, and triglycerides were 6.5%, 9.0% and 16% higher, respectively. Apolipoprotein B concentration remained unchanged. The results on LDL oxidizability were inconsistent. Plasma homocysteine decreased with 12.3% during the first 6 months of treatment in women with higher homocysteine concentrations at baseline. These values returned to baseline levels during the second half year of treatment.
  
  
  CONCLUSIONS
  This sequential hormone regimen induced beneficial changes in the conventional lipid and lipoprotein risk estimators, whereas the observed changes in the other markers remained inconclusive and/or of minor importance.
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital Nijmegen Sint Radboud, The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: van der Mooren
authors.forename: P N
authors.initials: PN
authors.lastname: Demacker
authors.forename: H J
authors.initials: HJ
authors.lastname: Blom
authors.forename: Y B
authors.initials: YB
authors.lastname: de Rijke
authors.forename: R
authors.initials: R
authors.lastname: Rolland
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage; D005260:Female; D006710:Homocysteine / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood; D008137:Longitudinal Studies; D008875:Middle Aged; D010084:Oxidation-Reduction; D017698:Postmenopause; D011446:Prospective Studies
chemical_list: D004966:Estrogens, Conjugated (USP); D008055:Lipids; D006710:Homocysteine